FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106489628> ?p ?o ?g. }

• W2106489628 endingPage "902" @default.
• W2106489628 startingPage "2891" @default.
• W2106489628 abstract "Bcl-2 is a key apoptosis-regulating protein that has been implicated in mechanisms of chemoresistance for a variety of malignancies by blocking programmed cell death. This study investigated the activity of the Bcl-2 antisense oligodeoxynucleotide (AS ODN) G3139 combined with free doxorubicin (F-DOX) or sterically stabilized liposomal doxorubicin (SL-DOX) to determine the role that drug pharmacodistribution properties may have on antitumor activity using a Bcl-2-expressing human breast solid tumor xenograft model. Administration of G3139 was able to delay the growth of MDA435/LCC6 cells compared with control ODN-treated animals; however, in all of the cases, tumors reestablished after AS ODN treatment. Western blot analyses of Bcl-2 levels of solid tumors showed a sequence-specific down-regulation of the Bcl-2 protein after four daily doses of G3139, which correlated with histological evidence of tumor cell death. Interestingly, the expression of Bcl-2 returned to pretreatment levels during the course of subsequent ODN administration, which suggested the development of resistance to continued Bcl-2 ODN treatment. The antitumor activity of ODN given in conjunction with either F-DOX or SL-DOX was also examined. The combination of G3139 and F-DOX was able to suppress the growth of MDA435/LCC6 cells beyond that obtained with either of the treatments given alone, indicative of synergistic action. Examination of the pharmacokinetics of F-DOX with systemic G3139 administration revealed that elevated tumor drug DOX levels were obtained compared with DOX treatment in the absence of G3139. This effect was sequence-specific and plasma DOX levels were unaffected by G3139 treatment, which indicated possible positive ODN-drug interactions at the tumor site. Combining G3139 with SL-DOX further increased the degree of antitumor activity. The improved efficacy of this combination was attributed to increased tumor drug levels that arise from the ability of SL-DOX to passively accumulate in solid tumors. These results suggest that additional benefits of Bcl-2 antisense ODN may be obtained when it is combined with liposomal formulations of anticancer drugs such as DOX." @default.
• W2106489628 created "2016-06-24" @default.
• W2106489628 creator A5047623272 @default.
• W2106489628 creator A5079602516 @default.
• W2106489628 creator A5089253181 @default.
• W2106489628 creator A5091206874 @default.
• W2106489628 date "2000-07-01" @default.
• W2106489628 modified "2023-09-27" @default.
• W2106489628 title "Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin." @default.
• W2106489628 cites W100870282 @default.
• W2106489628 cites W112005226 @default.
• W2106489628 cites W1543443055 @default.
• W2106489628 cites W1559053841 @default.
• W2106489628 cites W1588809288 @default.
• W2106489628 cites W1591166893 @default.
• W2106489628 cites W1748388485 @default.
• W2106489628 cites W1777880772 @default.
• W2106489628 cites W1936464499 @default.
• W2106489628 cites W1941582121 @default.
• W2106489628 cites W1986516374 @default.
• W2106489628 cites W198776403 @default.
• W2106489628 cites W1990548509 @default.
• W2106489628 cites W1997569032 @default.
• W2106489628 cites W2002273265 @default.
• W2106489628 cites W2027344275 @default.
• W2106489628 cites W2028065774 @default.
• W2106489628 cites W2040506871 @default.
• W2106489628 cites W2042760441 @default.
• W2106489628 cites W20453933 @default.
• W2106489628 cites W2064059721 @default.
• W2106489628 cites W2067401769 @default.
• W2106489628 cites W2084341407 @default.
• W2106489628 cites W2118878458 @default.
• W2106489628 cites W2135368384 @default.
• W2106489628 cites W2136885844 @default.
• W2106489628 cites W2140383812 @default.
• W2106489628 cites W2156246685 @default.
• W2106489628 cites W2158449037 @default.
• W2106489628 cites W2161580101 @default.
• W2106489628 cites W2162464751 @default.
• W2106489628 cites W2170314391 @default.
• W2106489628 cites W2259568108 @default.
• W2106489628 cites W2321782282 @default.
• W2106489628 cites W2330056755 @default.
• W2106489628 cites W39449442 @default.
• W2106489628 cites W2013185575 @default.
• W2106489628 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10914739" @default.
• W2106489628 hasPublicationYear "2000" @default.
• W2106489628 type Work @default.
• W2106489628 sameAs 2106489628 @default.
• W2106489628 citedByCount "26" @default.
• W2106489628 countsByYear W21064896282013 @default.
• W2106489628 countsByYear W21064896282016 @default.
• W2106489628 countsByYear W21064896282018 @default.
• W2106489628 countsByYear W21064896282021 @default.
• W2106489628 countsByYear W21064896282022 @default.
• W2106489628 crossrefType "journal-article" @default.
• W2106489628 hasAuthorship W2106489628A5047623272 @default.
• W2106489628 hasAuthorship W2106489628A5079602516 @default.
• W2106489628 hasAuthorship W2106489628A5089253181 @default.
• W2106489628 hasAuthorship W2106489628A5091206874 @default.
• W2106489628 hasConcept C104317684 @default.
• W2106489628 hasConcept C112705442 @default.
• W2106489628 hasConcept C185592680 @default.
• W2106489628 hasConcept C190283241 @default.
• W2106489628 hasConcept C2776415932 @default.
• W2106489628 hasConcept C2776694085 @default.
• W2106489628 hasConcept C2781303535 @default.
• W2106489628 hasConcept C31573885 @default.
• W2106489628 hasConcept C502942594 @default.
• W2106489628 hasConcept C54355233 @default.
• W2106489628 hasConcept C55493867 @default.
• W2106489628 hasConcept C86803240 @default.
• W2106489628 hasConcept C98274493 @default.
• W2106489628 hasConceptScore W2106489628C104317684 @default.
• W2106489628 hasConceptScore W2106489628C112705442 @default.
• W2106489628 hasConceptScore W2106489628C185592680 @default.
• W2106489628 hasConceptScore W2106489628C190283241 @default.
• W2106489628 hasConceptScore W2106489628C2776415932 @default.
• W2106489628 hasConceptScore W2106489628C2776694085 @default.
• W2106489628 hasConceptScore W2106489628C2781303535 @default.
• W2106489628 hasConceptScore W2106489628C31573885 @default.
• W2106489628 hasConceptScore W2106489628C502942594 @default.
• W2106489628 hasConceptScore W2106489628C54355233 @default.
• W2106489628 hasConceptScore W2106489628C55493867 @default.
• W2106489628 hasConceptScore W2106489628C86803240 @default.
• W2106489628 hasConceptScore W2106489628C98274493 @default.
• W2106489628 hasIssue "7" @default.
• W2106489628 hasLocation W21064896281 @default.
• W2106489628 hasOpenAccess W2106489628 @default.
• W2106489628 hasPrimaryLocation W21064896281 @default.
• W2106489628 hasRelatedWork W1967156938 @default.
• W2106489628 hasRelatedWork W2019493845 @default.
• W2106489628 hasRelatedWork W2020348505 @default.
• W2106489628 hasRelatedWork W2050614342 @default.
• W2106489628 hasRelatedWork W2059353851 @default.
• W2106489628 hasRelatedWork W2067689242 @default.
• W2106489628 hasRelatedWork W2074544404 @default.

• next